- Home
- MP vs ROIV Comparison
MP vs ROIV Comparison
Compare MP & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MP | ROIV |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MP | ROIV |
|---|---|---|
| Price | $49.93 | $21.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $70.92 | $24.31 |
| AVG Volume (30 Days) | 5.9M | ★ 8.2M |
| Earning Date | 02-19-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $232,742,000.00 | $20,329,000.00 |
| Revenue This Year | $36.77 | N/A |
| Revenue Next Year | $145.71 | $741.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 26.44 | N/A |
| 52 Week Low | $15.56 | $8.73 |
| 52 Week High | $100.25 | $23.47 |
Technical Indicators
Market Signals| Indicator | MP | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 35.03 | 53.08 |
| Support Level | $53.34 | $21.36 |
| Resistance Level | $55.50 | $22.72 |
| Average True Range (ATR) | 2.68 | 0.80 |
| MACD | -0.24 | -0.13 |
| Stochastic Oscillator | 2.96 | 45.71 |
Price Performance
Historical ComparisonAbout MP MP Materials Corp.
MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America. The company is also developing a rare earth metal, alloy, and magnet manufacturing facility in Fort Worth, Texas. The company's operations are organized into two reportable segments: Materials and Magnetics.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.